ROCK SPRINGS CAPITAL MANAGEMENT LP
Q2 2026 Form 13-F

BALTIMORE, MARYLAND
CIK 0001595725 · CRD 168648 · SEC-registered investment adviser
$2.0B Reported Value Total

ROCK SPRINGS CAPITAL reports 6 total accounts under management (AUM). There are 6 discretionary accounts valued at $2,426,287,072, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
2 funds · $2.4B gross asset value
Hedge Fund: $2.4B
Source: Form ADV filed 2026-03-24
Reported value
$2.0B
Quarter over quarter
+21.1%
Holdings
104
Top-10 concentration
44.0%

Key People

Form ADV owners & control persons
Gordon Margraf ("mark") Bussard
MEMBER/LIMITED PARTNER
Kris Harlan Jenner
MEMBER/LIMITED PARTNER
Nnamdi C Etoh
CHIEF FINANCIAL OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q2 2026 13F record

Q2 2026 13F filing summary

Q2 2026 Form 13F portfolio summary
Period of report June 30, 2026
Filed August 14, 2026
Form 13F-HR
Reported value $2.0B
Positions 104
Change in reported value +20.8%
New positions 17
Exited positions 13
Position turnover 25.6%
Top-10 concentration 44.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q2 2026 13F
Filed Aug 14, 2026
104 $2.0B
Q1 2026 13F
Filed May 15, 2026
100 $1.7B
Q4 2025 13F
Filed Feb 17, 2026
97 $2.0B
Q3 2025 13F
Filed Nov 14, 2025
91 $1.7B
Q2 2025 13F
Filed Aug 14, 2025
92 $1.6B
Q1 2025 13F
Filed May 15, 2025
95 $1.7B
Q4 2024 13F
Filed Feb 14, 2025
105 $2.6B
Q3 2024 13F
Filed Nov 14, 2024
107 $3.1B
Q2 2024 13F
Filed Aug 14, 2024
107 $3.3B
Q1 2024 13F
Filed May 15, 2024
109 $3.9B
Q4 2023 13F
Filed Feb 14, 2024
99 $4.1B
Q3 2023 13F
Filed Nov 14, 2023
116 $3.7B
Q2 2023 13F
Filed Aug 14, 2023
119 $4.2B
Q1 2023 13F
Filed May 15, 2023
116 $4.2B
Q4 2022 13F
Filed Feb 14, 2023
116 $4.2B
Q3 2022 13F
Filed Nov 14, 2022
123 $3.9B
Q2 2022 13F
Filed Aug 15, 2022
125 $3.4B
Q1 2022 13F
Filed May 16, 2022
128 $4.0B
Q4 2021 13F
Filed Feb 14, 2022
128 $4.3B
Q3 2021 13F
Filed Nov 15, 2021
145 $4.8B

31 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q2 2026

Largest Q2 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 RVMD REVOLUTION MEDICINES INC $207.0M 10.1%
2 TVTX TRAVERE THERAPEUTICS INC $123.8M 6.04%
3 LLY ELI LILLY & CO $118.4M 5.78%
4 MDGL MADRIGAL PHARMACEUTICALS INC $94.0M 4.59%
5 MIRM MIRUM PHARMACEUTICALS INC $93.4M 4.56%
6 RYTM RHYTHM PHARMACEUTICALS INC $76.9M 3.75%
7 KYMR KYMERA THERAPEUTICS INC $52.0M 2.54%
8 ARGX ARGENX SE $48.9M 2.39%
9 ASND ASCENDIS PHARMA A/S $45.0M 2.2%
10 XENE XENON PHARMACEUTICALS INC $41.3M 2.01%
11 SRRK SCHOLAR ROCK HLDG CORP $39.3M 1.92%
12 INSM INSMED INC $38.6M 1.88%
13 PEN PENUMBRA INC $36.5M 1.78%
14 GPCR STRUCTURE THERAPEUTICS INC $34.4M 1.68%
15 RARE ULTRAGENYX PHARMACEUTICAL IN $32.3M 1.58%
16 IRTC IRHYTHM HOLDINGS INC $32.1M 1.57%
17 ISRG INTUITIVE SURGICAL INC $30.4M 1.48%
18 AGLZZZZ AGILON HEALTH INC $28.1M 1.37%
19 UNH UNITEDHEALTH GROUP INC $26.5M 1.29%
20 CLDX CELLDEX THERAPEUTICS INC NEW $26.0M 1.27%

Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Similar Managers

Finding Similar Managers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings